Skip to content
Screener

Roivant Sciences ROIV EV / EBITDA

EV / EBITDA at other companies

Amgen logo
AmgenAMGN
15.7×+0.7×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
10.1×-0.2×
AbbVie logo
AbbVieABBV
19.8×—
Revvity logo
RevvityRVTY
16.7×-2.2×
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
4.6×—

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$25.37B+219%
Enterprise value$25.4B+219%
P/S3,368×+3,026×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0×0.0×
Current ratio16.7×-23.8×

Where this comes from

Calculated from Roivant Sciences’s reported figures.

enterprise value/ebitda=1.8×

Based on the most recent quarter.

The source filing: Roivant Sciences’s 10-Q, filed November 12, 2024. Open the filing →

Filed
Nov 12, 2024
Fiscal quarter
Q2 FY2024
Calendar quarter
Q3 2024
Accession
0001140361-24-046019

FAQ

What is Roivant Sciences's EV / EBITDA?
Roivant Sciences (ROIV) reported EV / EBITDA of 1.8× in Q3 2024.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Roivant Sciences's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude